▟ Vinebot intrinsic value, daily

← back

IQV IQVIA

pharma · valued with glm-5.2 medium conviction · deep-dived 2026-09-10

SELL
Intrinsic value$49.45
Price (at call)$256.98
Margin of safety -80.8%
vs market (rating basis) -33.3%

Model unavailable; showing baseline valuation.

⚠ LLM error: empty response; using baseline

The story

Value drivers

Revenue growth (Y1)4.2%
Terminal growth3.5%
Forecast horizon10y
Target operating margin13.8%
Years to target margin5
Sales-to-capital0.76
Beta1.19
Failure probability0.0%
Cost of capital (WACC)9.6%
Terminal WACC9.0%

Valuation bridge

PV of explicit FCFF8.66B
PV of terminal value13.35B
Equity value8.14B
÷ shares → per share$49.45

News

bullish +0.60 · 8 articles

  • IQVIA (IQV): Buy, Sell, or Hold Post Q2 Earnings?
  • 1 Profitable Stock with Solid Fundamentals and 2 That Underwhelm
  • VEEV Raises FY27 Outlook as Vault CRM and AI Momentum Accelerate Fast
  • Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?
  • This Payroll Software Company Bought Back 20% of Its Shares and the Stock Has Nearly Doubled Since April
  • Beyond The Cloud Giants: What Could Power NVIDIA Stock From Here?
  • Q2 Earnings Roundup: IQVIA (NYSE:IQV) And The Rest Of The Drug Development Inputs & Services Segment
  • How Strong Q2 Beat And Raised 2026 Guidance At IQVIA Holdings (IQV) Has Changed Its Investment Story

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 17.70B 4.2% 13.8% 2.06B 936.86M 1.12B 1.02B
2 18.43B 4.1% 13.8% 2.14B 957.94M 1.18B 986.16M
3 19.18B 4.1% 13.8% 2.23B 978.40M 1.25B 950.55M
4 19.94B 4.0% 13.8% 2.32B 998.14M 1.32B 915.35M
5 20.72B 3.9% 13.8% 2.41B 1.02B 1.39B 880.62M
6 21.51B 3.8% 13.8% 2.50B 1.04B 1.46B 846.39M
7 22.31B 3.7% 13.8% 2.59B 1.05B 1.54B 812.73M
8 23.13B 3.7% 13.8% 2.69B 1.07B 1.62B 779.68M
9 23.96B 3.6% 13.8% 2.78B 1.08B 1.70B 747.27M
10 24.80B 3.5% 13.8% 2.88B 1.10B 1.78B 715.54M

⚠ Extreme gap to market price — large, heavily-covered stocks are rarely mispriced this much; the gap likely embeds disruption, decline, or balance-sheet risk the model underweights. Treat as a flag to investigate, not a verdict.

History

DatePriceIntrinsicMoSRating
2026-09-10$256.98 $49.45 -80.8% SELL
2026-08-10$238.70 $67.78 -71.6% HOLD
2026-07-07$205.97 $81.43 -60.5% HOLD
2026-06-23$171.28 $83.46 -51.3% HOLD